Bridges Investment Management Inc. Purchases 3,298 Shares of Johnson & Johnson $JNJ

Bridges Investment Management Inc. boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.4% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 77,996 shares of the company’s stock after buying an additional 3,298 shares during the quarter. Bridges Investment Management Inc.’s holdings in Johnson & Johnson were worth $11,914,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Brighton Jones LLC lifted its position in shares of Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after buying an additional 6,332 shares during the last quarter. Wealth Group Ltd. bought a new stake in Johnson & Johnson in the 1st quarter valued at $218,000. GAMMA Investing LLC lifted its holdings in Johnson & Johnson by 48.0% during the 1st quarter. GAMMA Investing LLC now owns 43,508 shares of the company’s stock valued at $7,215,000 after purchasing an additional 14,118 shares during the last quarter. Kiley Juergens Wealth Management LLC boosted its position in Johnson & Johnson by 2.5% during the first quarter. Kiley Juergens Wealth Management LLC now owns 17,909 shares of the company’s stock worth $2,970,000 after purchasing an additional 435 shares during the period. Finally, Community Bank N.A. increased its holdings in shares of Johnson & Johnson by 4.0% in the first quarter. Community Bank N.A. now owns 47,656 shares of the company’s stock valued at $7,903,000 after purchasing an additional 1,835 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Sanford C. Bernstein boosted their price objective on Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a report on Monday, October 6th. Citigroup upped their target price on Johnson & Johnson from $213.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday. Royal Bank Of Canada reissued an “outperform” rating and set a $209.00 price target on shares of Johnson & Johnson in a report on Friday, October 10th. Finally, Argus set a $210.00 price objective on Johnson & Johnson in a report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $199.59.

Johnson & Johnson Stock Up 0.6%

NYSE JNJ opened at $193.27 on Friday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The company has a market cap of $465.45 billion, a price-to-earnings ratio of 18.65, a PEG ratio of 2.26 and a beta of 0.40. The company has a 50 day moving average of $180.49 and a 200-day moving average of $164.80. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $194.40.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%. On average, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.